Generation of G51D and 3D mice reveals decreased α-synuclein tetramer-monomer ratios promote Parkinson’s disease phenotypes
Open Access
- 29 February 2024
- journal article
- research article
- Published by Springer Nature in npj Parkinson's Disease
- Vol. 10 (1) , 1-12
Abstract
Mutations in the α-Synuclein (αS) gene promote αS monomer aggregation that causes neurodegeneration in familial Parkinson’s disease (fPD). However, most mouse models expressing single-mutant αS transgenes develop neuronal aggregates very slowly, and few have dopaminergic cell loss, both key characteristics of PD. To accelerate neurotoxic aggregation, we previously generated fPD αS E46K mutant mice with rationally designed triple mutations based on the α-helical repeat motif structure of αS (fPD E46K→3 K). The 3 K variant increased αS membrane association and decreased the physiological tetramer:monomer ratio, causing lipid- and vesicle-rich inclusions and robust tremor-predominant, L-DOPA responsive PD-like phenotypes. Here, we applied an analogous approach to the G51D fPD mutation and its rational amplification (G51D → 3D) to generate mutant mice. In contrast to 3 K mice, G51D and 3D mice accumulate monomers almost exclusively in the cytosol while also showing decreased αS tetramer:monomer ratios. Both 1D and 3D mutant mice gradually accumulate insoluble, higher-molecular weight αS oligomers. Round αS neuronal deposits at 12 mos immunolabel for ubiquitin and pSer129 αS, with limited proteinase K resistance. Both 1D and 3D mice undergo loss of striatal TH+ fibers and midbrain dopaminergic neurons by 12 mos and a bradykinesia responsive to L-DOPA. The 3D αS mice have decreased tetramer:monomer equilibria and recapitulate major features of PD. These fPD G51D and 3D mutant mice should be useful models to study neuronal αS-toxicity associated with bradykinetic motor phenotypes.Keywords
Funding Information
- U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NS109510, NS099328, NS083845)
- U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke
- U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke
This publication has 74 references indexed in Scilit:
- The Parkinson-Associated Toxin Paraquat Shifts Physiological α-Synuclein Tetramers toward Monomers That Can Be Calpain-Truncated and Form OligomersThe American Journal of Pathology, 2023
- A Brain-Penetrant Stearoyl-CoA Desaturase Inhibitor Reverses α-Synuclein ToxicityNeurotherapeutics, 2022
- Brain region-specific susceptibility of Lewy body pathology in synucleinopathies is governed by α-synuclein conformationsActa Neuropathologica, 2022
- A Stearoyl–Coenzyme A Desaturase Inhibitor Prevents Multiple Parkinson Disease Phenotypes in α‐Synuclein MiceAnnals of Neurology, 2020
- Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathyJournal of Neurology, 2013
- G51D α‐synuclein mutation causes a novel Parkinsonian–pyramidal syndromeAnnals of Neurology, 2013
- α-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson’s disease and multiple system atrophy?Acta Neuropathologica, 2013
- N‐terminal acetylation is critical for forming α‐helical oligomer of α‐synucleinProtein Science, 2012
- Clinical progression in Parkinson disease and the neurobiology of axonsAnnals of Neurology, 2010
- Motor impairment and aberrant production of neurochemicals in human α-synuclein A30P+A53T transgenic mice with α-synuclein pathologyBrain Research, 2009